Compare OPRX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | TNXP |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 201.0M |
| IPO Year | N/A | N/A |
| Metric | OPRX | TNXP |
|---|---|---|
| Price | $12.35 | $16.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $14.83 | ★ $70.00 |
| AVG Volume (30 Days) | 242.0K | ★ 509.0K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | $10,299,000.00 |
| Revenue This Year | $19.77 | $2.96 |
| Revenue Next Year | $11.33 | $750.19 |
| P/E Ratio | $6,842.22 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $6.76 |
| 52 Week High | $22.25 | $69.97 |
| Indicator | OPRX | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 39.76 |
| Support Level | $12.66 | $15.93 |
| Resistance Level | $13.78 | $19.35 |
| Average True Range (ATR) | 0.60 | 1.06 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 2.97 | 10.37 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.